Rhythm Pharmaceuticals Announces Board Changes with Kim Popovits' Appointment and Ed Mathers' Departure

Apr 03, 2026 14:09 UTC

RYTM

Short term

Rhythm Pharmaceuticals Inc. (RYTM) has appointed Kim Popovits to its board of directors, effective immediately. The change follows the departure of long-time director Ed Mathers, who has served on the board since 2013.

Kim Popovits has been appointed to Rhythm Pharmaceuticals' board of directors.
Ed Mathers, who has served on the board since 2013, is departing.
Rhythm Pharmaceuticals' stock closed at $86.29 on April 2, 2026, down 2.08%.
The board changes are part of routine corporate governance adjustments.

Rhythm Pharmaceuticals Inc. (RYTM) announced on April 3, 2026, the addition of Kim Popovits to its board of directors. This appointment coincides with the departure of Ed Mathers, who has been a board member since 2013. The company did not disclose specific details regarding the rationale for the changes or Popovits' prior experience. On the Nasdaq, Rhythm Pharmaceuticals closed trading at $86.29 on April 2, 2026, reflecting a 2.08% decline from the previous day's close. The stock's performance on Thursday may be influenced by broader market conditions or company-specific factors unrelated to the board changes. As a mid-cap biotech firm, Rhythm Pharmaceuticals' corporate governance updates typically have limited impact on its stock price or industry peers. Investors and analysts are likely to monitor future developments for any strategic implications arising from the board transition.